Mohammad AskarPublic working copy · medical review pending

nAMD treatment intervals · 029

nAMD: appraising longer treatment intervals

Longer intervals may reduce burden when visual function and disease control are maintained. PULSAR, extension data, teaching cases and systemic hypotheses address different questions and are appraised separately.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Non-inferiority under a trial protocol does not promise a particular interval. Function, OCT, individual risk and follow-up guide management; unconfirmed original figures remain explicitly unresolved.

Terminology and draft status

Terminology review is not complete. Actual inspected entries for retina and macular degeneration and the ambiguous result are recorded in the terminology ledger; they do not approve the whole translation.

01Assess treatment burden

Anti-VEGF treatment can preserve vision in neovascular age-related macular degeneration (nAMD) but requires long-term care. Longer intervals help only when disease control and reliable follow-up are maintained. VEGF means vascular endothelial growth factor. 5

The original attributes preference for longer intervals in 73% of patients and excessive treatment frequency in 88% of doctors to the Barometer survey. Nearly half of patients reportedly found treatment too frequent; in a German group, 44.5% had received 11–60 injections and over 20% more than 60. Source, survey dates and denominators remain unverified. 6

The lecture also reports travel burden in 40%, cost difficulties in over a quarter, and anxiety about treatment or dependence on carers. Travel, mobility and companions matter individually; the survey figures are not verified service-level rates here. 6

Mecklenburgische Seenplatte is described as larger than Saarland with an ageing, declining population; journeys of up to 1.5 hours one way illustrate burden. This is a regional example, not a measured national dataset. 6

The projection from 67 million affected Europeans in 2015 to 77 million by 2050 concerns all AMD, not exclusively nAMD. The claim that almost 60% of German ophthalmologists are at least 50 and will retire within 10–15 years also lacks a verified original source; neither figure is a verified current census. 6

02PULSAR: what was randomized?

PULSAR is a global randomized, double-masked phase-III trial in treatment-naive nAMD: 1011 people were randomized and 1009 treated. After 3 initial monthly injections, aflibercept 8 mg every 12 or 16 weeks (8q12/8q16) was compared with 2 mg every 8 weeks (2q8); disease-based shortening was possible from week 16. The original description “over 1,000” concerns this trial population. 1

At 48 weeks, mean best-corrected visual acuity (BCVA) gains were 6.7 and 6.2 versus 7.6 letters. The non-inferiority margin was 4 letters; both 8-mg regimens met the primary endpoint, not a general superiority claim. 1

Randomization and masking strengthen the comparison. Manufacturer funding and the unread full reports, protocols and supplements limit complete bias appraisal here; a positive abstract does not establish every subgroup result or rare harm. 1 2

At 96 weeks, 869 of the 1009 treated participants completed the trial; reported acuity gains were 5.6/5.5/6.6 letters. Among completers, mean injection counts were 9.7/8.2/12.8 for 8q12/8q16/2q8; distinguish this selected group from the randomized starting population and pooled figures. 2

The table retains all original cells: 12.8 and pooled 8.9 through week 96, and 4.7 after switching and 3.8 during weeks 96–156. The pooling and extension phase cannot be reconstructed from the accessed abstracts; they remain unconfirmed lecture claims, not a new controlled switch comparison. 2 6

PULSAR: what was randomized?
Treatment armMean injections through week 96; original claimMean injections weeks 96–156; unconfirmed extension claim
Aflibercept 2 mg (q8)12.84.7 after switch to 8 mg; denominator unresolved
Aflibercept 8 mg (q12/q16)8.9 pooled; not reconstructed3.8; denominator unresolved

03Separate intervals from extension claims

The 96-week abstract reports last assigned intervals for 8q12 of at least 12 weeks in 87%; for 8q16, at least 16 weeks in 78%, at least 20 in 53%, and 24 weeks in 31%. These arm-specific completer figures must not become a single success rate for all 8-mg patients. 2

The original instead gives pooled values of 88% at least 12 weeks, 70–80% at 12 or 16 weeks, and nearly 50% at least 20 weeks. Its claims of 75% without shortening on 8q12 and 70% on 8q16 also remain unreconciled; definitions, selection and denominators are unresolved. 6

For week 156, the lecture describes switching the original 2-mg group to 8 mg every 12 weeks without another loading course; 8 in 10 reportedly maintained at least 12 weeks. The extension report is unread: selection, attrition and lack of an unchanged comparator limit any inference about switching. 6

04OCT findings, subgroups and safety

The original reports a dry central retina after 3 monthly doses at week 16 in 63% versus52% (p=0.0002). The exact table was not appraised; the figures remain unconfirmed lecture claims about an anatomical endpoint, not proof of proportionately greater visual benefit. 6

Another original claim links dryness at week 4 to maintaining16-week intervals through week 48 in 80%, versus66% with early residual fluid. That would still leave about two-thirds with residual fluid on long intervals; the exploratory association is not verified as validated treatment selection or individual prediction. 6

The lecture claims consistent effects across BCVA, central subfield thickness (CST), CNV type and lesion size, and ethnicity. Without appraised interaction tests, precision and multiplicity, this establishes neither absence of heterogeneity nor equivalence in previously treated eyes. CNV means choroidal neovascularization. 1 2 6

Similar ocular event rates in the randomized trial do not guarantee equal rare risks. The original claim of no endophthalmitis or occlusive vasculitis in 8-mg arms over2 years needs the exact safety table and denominators; continue to consider pressure elevation and inflammation. 1 2 4 6

05The two cases and interval decisions

Case 73: A treatment-naive73-year-old woman reported metamorphopsia over4 weeks with acuity0.2. After3 monthly8-mg injections, acuity0.4, resolved distortion and dry OCT were described; some intraretinal fluid recurred at 8 weeks, followed by controlled treat-and-extend (T&E). The teaching case illustrates monitoring rather than automatic extension, not a causal comparative effect. 6

Case 85: An85-year-old man with activity after 10previous off-label injections every8 weeks switched to 8 mg. A new loading course reportedly produced dryness and12-week maintenance with good acuity; the uncontrolled course, selection and prior treatment do not establish a general reloading recommendation. 6

Before extending, assess function and OCT activity; intraretinal fluid and stability matter, without automatically jumping to the longest interval. The original suggestion to switch whenever intervals are no longer than 8 weeks is an expert view, not a universal rule. 5 6

The accessed EU8 mg product information permits individualized maintenance after 3 initial monthly injections and later intervals up to 6 months when stable. In stable switches, the interval may be maintained or extended after the first injection; distinguish trial protocol from current labeling, without universal reloading. 4

Infection, severe active intraocular inflammation, injection-related retinal complications and pressure elevation require attention to contraindications and monitoring. Consider systemic cautions and recent vascular events individually; fewer injections do not remove the need for review. 4

06Interpret systemic factors and saccharin

The original “bipolar” response distribution and image of a systemically fuelled or suppressed fire are conceptual models. Genetics, nutrition with an AREDS connection, smoking and physical activity remain relevant topics but do not prove this model or an individual anti-VEGF response; AREDS is not a blanket supplement rule for all AMD. The model separates chronically active neovascularization requiring frequent treatment from controlled disease with long intervals; this claimed two-peak distribution is not validated here. The original emphasizes smoking as a strong environmental factor and cites experimental CNV associations for physical activity, not a proven substitute for treatment. 6

The saccharin study combined a cross-sectional analysis of 46 nAMD patients with laser-induced CNV in mice. Measured saccharin metabolites were associated with better lesion control (p=.004) and absence of subretinal hyperreflective material (p=.015); this was not a randomized dietary trial. 3

The mouse model showed less leakage, bleeding and fibrosis. A40% reduction in mononuclear phagocytes at p=.06 is not statistically significant; the TAS1R3 receptor proposal is mechanistic. Confounding, reverse causation, multiple testing and animal-to-human translation limit clinical inference; the full report is unread. 3

What are the main learning points of this nAMD lecture?

Non-inferiority under a trial protocol does not promise a particular interval. Function, OCT, individual risk and follow-up guide management; unconfirmed original figures remain explicitly unresolved.

Which findings require urgent assessment?

Seek immediate medical help for sudden visual deterioration, severe pain or a new visual field defect.

References and access status

  1. 1
  2. 2
    Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.

    PULSAR96: complete actual NCBI abstract read; completer and arm-specific intervals distinguished. Full report and156-week extension unread.

  3. 3
    Exploring the Impact of Saccharin on Neovascular Age-Related Macular Degeneration: A Comprehensive Study in Patients and Mice.

    Complete actual NCBI abstract read; cross-sectional plus animal model, not a human dietary RCT. Full report unread.

  4. 4
    EMA Eylea EU product information

    EMA EU product information: printed pp.64–68, sections4.1–4.4 for 8 mg actually read; not all167pages or indications.

  5. 5
    DOG/RG/BVA nAMD anti-VEGF statement15October2022

    DOG/RG/BVA15.10.2022: key recommendations pp.2–6 actually read; not all26pages. Predates8 mg and is not current8 mg dosing guidance.

  6. 6
    Original exported teaching text

    Complete original read; surveys, extension figures and attribution not independently verified. No traceable original recording URL.